Keith Harris

Keith Harris

Auto-generated profile, based on publicly available information

Keith Harris

Clinical Toxicology Unit Princess Alexandra Hospital Brisbane Australia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2025 in Drug and Alcohol Review
Verified
Journal Article
Closed access
KIKatherine Z Isoardi
Katherine Z Isoardi
SASam Alfred
Sam Alfred
CWCourtney Weber
Courtney Weber
KHKeith Harris
Keith Harris
JSJessamine Soderstrom
Jessamine Soderstrom
EIEDNA and EDNAV Investigators
EDNA and EDNAV Investigators

23 May 2025 in Journal of Hepatology
Verified
Journal Article
Open access
Geoffrey IsbisterGeoffrey Isbister
Geoffrey Isbister
ACAngela Chiew
Angela Chiew
NBNicholas Buckley
Nicholas Buckley
KHKeith Harris
Keith Harris
IBIngrid Berling
Ingrid Berling
KIKatherine Isoardi
Katherine Isoardi
Paracetamol is a common overdose worldwide. Early acetylcysteine treatment can prevent hepatotoxicity. Multiple intravenous acetylcysteine regimens exist; the commonest recommending 300mg/kg over 20h. We investigated the effectiveness and safety of a shorter regimen in paracetamol overdoses ≤30g. In a multicentre non-inferiority randomised controlled trial, 204 patients from three hospitals with acute paracetamol overdose ≤ 30g presenting within 8h, were randomised to standard 20h acetylcysteine (200mg/kg/4h, 100mg/kg/16h) regimen or short 12h acetylcysteine (200mg/kg/4h, 50mg/kg/8h) regimen. The primary outcome was the absolute difference between alanine transaminase (ALT) 24h post-ingestion and admission ALT (ΔALT24). Secondary outcomes included ALT>150U/L at 24h and double admission ALT, systemic hypersensitivity and gastrointestinal adverse effects. The two groups were similar in age, gender, dose ingested, paracetamol concentration, baseline ALT, hospital, charcoal administration and time until acetylcysteine. The shorter regimen was non-inferior to the standard regimen. ΔALT24 for 107 patients given the shorter regimen was median -2U/L (Interquartile range [IQR]:-7 to 1U/L) compared to 97 given the standard regimen, median -1U/L (IQR:-5 to 1.5U/L); difference in medians of -1U/L; 95% confidence interval:-3 to 1U/L; less than the upper non-inferiority margin of 5). No patient receiving the shorter regimen had a 24h ALT double admission and >150U/L, compared to one receiving the standard regimen. No patient had an ALT>1000U/L. Systemic hypersensitivity reactions were similar between groups [9/107 (8%) for short versus 10/97 (10%) standard regimen]. Gastrointestinal adverse effects occurred in 78/107 patients (73%) receiving the short versus 63/97 (65%) receiving the standard regimen. The shorter 12h acetylcysteine regimen had the same effectiveness and safety as the standard 20h regimen in acute paracetamol overdoses ≤30g, almost halving the length of treatment required. Australian New Zealand Clinical Trials Registry number ACTRN12616001617459.

6 November 2020 in Emergency Medicine Australasia
Verified
Journal Article
Open access
PDF file
MFMichael Fry
Michael Fry
KHKeith Harris
Keith Harris
KIKatherine Z Isoardi
Katherine Z Isoardi
Click on the article title to read more.

21 July 2019 in Emergency Medicine Australasia
Verified
Journal Article
Closed access
PDF file
KHKeith Harris
Keith Harris
CPColin B Page
Colin B Page
SSSikta Samantray
Sikta Samantray
LPLachlan Parker
Lachlan Parker
ABAndrew Ja Brier
Andrew Ja Brier
KIKatherine Z Isoardi
Katherine Z Isoardi

5 September 2024 in Clinical Toxicology
Verified
Journal Article
Closed access
KIKatherine Z. Isoardi
Katherine Z. Isoardi
KHKeith Harris
Keith Harris
ECElizabeth Currey
Elizabeth Currey
NBNicholas A. Buckley
Nicholas A. Buckley
Geoffrey IsbisterGeoffrey Isbister
Geoffrey Isbister
Naloxone is an effective antidote, but its short half-life means repeated doses, and infusions are often required. We investigated the effectiveness of adding intramuscular naloxone to titrated intravenous naloxone in opioid overdose in preventing recurrence of respiratory depression. This double-blinded randomised placebo-controlled trial was conducted in patients with suspected opioid poisoning and respiratory depression (respiratory rate <10 breaths/min or oxygen saturation <93%). Patients were randomised to receive either intramuscular naloxone 1,600 µg or saline placebo. All patients received titrated intravenous naloxone 100 µg and were managed on an opioid poisoning care pathway. The primary outcome was recurrence of respiratory depression within 4 h. Secondary outcomes were the proportion receiving naloxone infusions, number of naloxone boluses administered, reversal of respiratory depression at 10 min, and precipitation of opioid withdrawal (any symptom). Recurrence of respiratory depression within 4 h was less common in 28/69 (41%) patients receiving intramuscular naloxone versus 48/67 (72%) patients receiving placebo (difference 31%, 95% CI: 13-46%; P < 0.001). Fewer naloxone infusions (5/69; 7% versus 25/67; 37%, difference 30%, 95% CI: 15 to 55%; P < 0.001) and fewer naloxone doses were administered (median 2, IQR: 1 to 5, versus median 5, IQR: 2 to 8; P = 0.001) in the intramuscular group. Reversal of respiratory depression at 10 min was similar between groups (51/69; 74% intramuscular naloxone versus 47/67; 70% placebo; P = 0.703). Opioid withdrawal occurred in 35/69 (51%) given intramuscular naloxone compared to 28/67 (42%) in the placebo group (difference 9%; 95% CI: -8 to 27%; P = 0.308). The favourable pharmacokinetics of intramuscular naloxone, particularly its longer duration of activity, likely explains the improved effectiveness with lower recurrence of respiratory depression. The addition of intramuscular naloxone 1,600 µg to titrated intravenous naloxone prolonged effective reversal of respiratory depression, with fewer naloxone doses and infusions given, and no significant difference in patients developing withdrawal.

2 November 2023 in Clinical Toxicology
Verified
Journal Article
Closed access
JAJessica Armstrong
Jessica Armstrong
KHKeith Harris
Keith Harris
CWCarol Wylie
Carol Wylie
KIKatherine Z. Isoardi
Katherine Z. Isoardi
Stonefish envenomation results in localized severe pain and swelling and systemic features, including vomiting, arrhythmia, pulmonary oedema, and possibly death. There are limited data regarding the effectiveness of the available antivenom. The aim of this series is to characterize presentations of patients with suspected stonefish envenomation and investigate treatment, including antivenom. This is a retrospective observational series of suspected stonefish envenomation as reported to the Queensland Poisons Information Centre or Princess Alexandra Hospital Clinical Toxicology Unit from July 2015 to January 2023. Patients were identified through the databases held by both the Centre and Unit, and data on clinical features and investigations were collected from the patient's electronic medical record. There were 87 suspected stonefish envenomations from July 2015 to January 2023. The median age was 26 (range: 5-69) years, and 69 (79 per cent) patients were male. Pain was reported in 85 (98 per cent) with a median peak pain score of 10 (range 4-12; three rated their pain greater than 10/10). A clear wound was documented in 64 (74 per cent), with local swelling in 63 (72 per cent). A foreign body was retained in eight (9 per cent) presentations. Systemic symptoms were rare, with vomiting in four (5 per cent) and dizziness in two (2 per cent) presentations. There were no instances of hypotension, arrhythmia, or pulmonary oedema. Hot water was administered in 72 (83 per cent) presentations. Oral analgesia was given in 55 (63 per cent). Parenteral analgesia was given in 53 (61 per cent), most commonly opioids. Local anaesthetic block was performed in 19 presentations (22 per cent), with effectiveness documented in 16/19 (84 per cent). Five patients received antivenom for intractable pain, and all received subsequent parenteral analgesia or local anaesthetic block. Stonefish envenomation is characterized by severe pain. Systemic symptoms were rare and not severe in this series. Local anaesthetic block appeared to be the most effective intervention for severe pain when performed. Antivenom appeared to be ineffective in managing pain.